Celularity Inc (CELU): Total Assets
$107.33M
As of 2025-12-31
$96.17M
As of 2026-06-30
-35.6%
3-year compound annual growth
-24.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $107.33M | -19.1% | 2026-04-30, Balance as of period end |
| 2024-12-31 | $132.68M | -7.8% | 2026-04-30, Balance as of period end |
| 2023-12-31 | $143.89M | -64.1% | 2025-05-08, Balance as of period end |
| 2022-12-31 | $401.07M | -3.2% | 2024-07-30, Balance as of period end |
| 2021-12-31 | $414.13M | -3.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $431.01M | n/c | 2022-03-31, Balance as of period end |
| 2019-12-31 | $291.61M | n/m | 2021-05-24, Balance as of period end |
| 2018-12-31 | $174.5K | n/a | 2020-03-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $42.21M | +31.1% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $246.44M | +142.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $127.04M | -38.7% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
Compare CELU, CUE, TRDA, ALMS side by side · Screen every company in Pharmaceutical Preparations ↗